companies / mosanna-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-05 json
| total_raised | 80,000,00080.0M | ○ |
|---|---|---|
| founded | 2023 | |
| hq | Basel Switzerland | |
| industry | unknown | |
| stage | series-a |
Mosanna Therapeutics is building a nasal-spray drug for obstructive sleep apnea that reactivates upper-airway muscles during sleep instead of forcing the airway open mechanically. It targets the millions of OSA patients who reject or fail CPAP. The pharmacological approach restores a natural reflex rather than competing on mask comfort.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-06-01 | series-a | 80,000,00080.0M | null | ○ |
WordPress 7.0, Apache HTTP Server, MonsterInsights 10.2.0, Yoast SEO 27.6, Google Analytics, Google Tag Manager, Slider Revolution, jQuery Migrate 3.4.1, PHP, DoubleClick Floodlight, MySQL, jquery 3.
| fact | status | src |
|---|---|---|
| Series A, $80.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |